Scancell Holdings Regulatory News (SCLP)

23 October 2019

Scancell Holdings plc

("Scancell" or the "Company")

Directorate Change

Scancell Holdings plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, is pleased to announce the appointment of Dr Ursula Ney as a Non-Executive Director of the Company with immediate effect, replacing Dr Matthew Frohn who is standing down on 31 October 2019 after more than twelve years of service to the Company.

Dr Ney has over thirty years' experience in the pharmaceutical and biotechnology industry, including twenty years in senior leadership roles that also encompassed Executive and Non-Executive Board positions. She has broad experience of biologic and small molecule drug development across a range of therapeutic areas having been Director of Drug Development and on the Board of Celltech plc and later Chief Operating Officer and Executive Director of Antisoma plc. Most recently, she was Chief Executive Officer of Genkyotex SA. She was on the Board of Discuva Ltd and is currently also a Non-Executive Director of Proteome Sciences plc.

Dr Ney's early career was spent at Sandoz (Switzerland) and Roche (UK). She has a PhD from the Royal Free Hospital Medical School and an MBA from Middlesex University Business School.

Commenting on the appointment, Dr John Chiplin Chairman of Scancell, said:

"I am pleased to welcome Ursula to the Board of Scancell. Ursula's extensive late stage development experience in the biotech sector will be invaluable as the Company continues to develop its product pipeline. I'd also like to take this opportunity to thank Matthew Frohn for the invaluable contributions he has made to the Company since he was first appointed to the Board in 2006. We wish him well in his future endeavours."

Dr Ursula Ney commented:

"I am delighted to be joining the Scancell Board at this exciting time and look forward to working with the team in realising the potential of the ImmunoBody®, Moditope® and AvidiMab™ platforms."

Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies 

The following information is disclosed pursuant to Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies in relation to Dr Ursula Mary Ney, aged 67:

As of the date of this announcement, Dr Ursula Ney holds no ordinary shares in the capital of the Company.

Save as disclosed above there are no additional disclosures to be made in accordance with Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.

For Further Information:

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.

ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system. They have the potential to be used as monotherapy or in combination with checkpoint inhibitors and other agents. This platform has the potential to enhance tumour destruction, prevent disease recurrence and extend survival.

·; SCIB1, the lead programme, is being developed for the treatment of melanoma. A phase 1/2 clinical trial has so far successfully demonstrated survival data of more than five years.

·; SCIB2 is being developed for the treatment of non-small cell lung cancer and other solid tumours. Scancell has entered into a clinical development partnership with Cancer Research UK (CRUK) for SCIB2.

Moditope® represents a completely new class of potent and selective immunotherapy agents based on stress-induced post-translational modifications (siPTM). It stimulates the production of killer CD4 T cells which overcome the immune suppression induced by tumours, allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system. Moditope® alone, or in combination with other agents, has the potential to treat a wide variety of cancers.

·; Modi-1 is being developed for the treatment of solid tumours including triple negative breast cancer, ovarian cancer and head and neck cancer.

AvidiMab™ is a patent protected technology platform which increases the avidity of human antibodies by promoting non-covalent Fc-Fc interactions. This modification induces the direct tumour cell killing properties of Scancell's anti-glycan monoclonal antibodies (mAbs) but has broad potential to increase the avidity or potency of any therapeutic monoclonal antibody including those being developed for autoimmune diseases, as well as cancer.

For further details, please see our website: www.scancell.co.uk